

Unaudited Financial Statements Optimal Medicine Limited

For the year ended 30 September 2018



Company No. 07004137

Company Information

Company registration number

07004137

Registered office

4th Floor
Griffin Court
15 Long Lane
London
EC1A 9PN

Directors

G Cerroni

Statement of Comprehensive Income

	Note	Year ended 30 September 2018 £	Year ended 30 September 2017 £
Administrative expenses		-	(312,482)
Loss after tax and total comprehensive expense for the financial year		-	(312,482)

Statement of Financial Position

	Note	30 September 2018		30 September 2017	
		£	£	£	£
Capital and reserves					
Called up share capital	2		193		193
Share premium	3		2,997,739		2,997,739
Capital redemption reserve	3		225		225
Profit and loss account	3		<u>(2,998,157)</u>		<u>(2,998,157)</u>
Total shareholders' funds			<u>-</u>		<u>-</u>

Statements

- For the year ending 30 September 2018 the company was entitled to exemption under section 480 of the Companies Act 2006 relating to dormant companies.
- The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
- These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime

Approved by Director on 15 January 2019:



Giulio Cerroni

Director

Company registration number: 07004137

Notes to the financial statements

1 Summary of significant accounting policies

General information

Optimal Medicine Limited is a private limited company incorporated and domiciled in England and Wales (registration number: 07004137).

The Company is a wholly owned subsidiary of IXICO Technologies Limited and its ultimate parent company is IXICO plc which prepares publicly available consolidated financial statements in accordance with IFRS. This Company is included in the consolidated financial statements of IXICO plc for the year ended 30 September 2018. These accounts are available from the registered office at 4th Floor, Griffin Court, 15 Long Lane, London, EC1A 9PN.

At 30 September 2017, the trade and assets of Optimal Medicine Limited were transferred to its immediate parent, IXICO Technologies Limited and the Company has ceased trading.

During year ended 30 September 2018, the Company had no accounting transactions and the company is dormant.

Basis of preparation

The financial statements of the Company have been prepared in accordance with applicable accounting standards and in accordance with Financial Reporting Standard 101 – 'The Reduced Disclosure Framework' (FRS 101). The principal accounting policies adopted in the preparation of these financial statements are set out below. These policies have all been applied consistently throughout the period unless otherwise stated.

The financial statements of the Company have been prepared under the historical cost convention and the financial information is presented in sterling.

Equity instruments

Equity instruments issued by the Company are recorded at the proceeds received, net of direct issue cost.

Share capital and reserves

Called up share capital represents the nominal value of shares that have been issued.

Share premium account represents the excess over nominal value of the fair value of consideration received for equity shares, net of expenses of the share issue.

Capital redemption reserve records the nominal value of shares repurchased by the company.

Notes to the financial statements

2 Share capital

	30 September 2018 £	30 September 2017 £
Allotted, called up and fully paid		
11,475 Ordinary shares of £0.01 each	115	115
8,601 A Ordinary shares of £0.001 each	9	9
25,000 B Ordinary shares of £0.001 each	25	25
34,400 C Ordinary shares of £0.001 each	34	34
1,001 Incentive shares of £0.01 each	10	10
	<u>193</u>	<u>193</u>

Rights of shares

Ordinary shares of £0.01 each

One vote per share on a poll, except where the shareholder ceases to be an employee, director or consultant in which case the shares shall not carry voting rights unless determined by the Board; one equal right per share in any share dividend declared; one equal right per share in the distribution of any surplus due to the shareholders on a winding-up or other return of capital; no redemption rights attach to these shares.

A Ordinary shares of £0.001 each

One vote per share on a poll, except where the shareholder ceases to be an employee, director or consultant in which case the shares shall not carry voting rights unless determined by the Board; one equal right per share in any share dividend declared; one equal right per share in the distribution of any surplus due to the shareholders on a winding-up or other return of capital; no redemption rights attach to these shares.

B Ordinary shares of £0.001 each

No voting rights attached to these shares; one equal right per share in any share dividend declared; one equal right per share in the distribution of any surplus due to the shareholders on the winding-up or other return of capital; redemption rights attach to these shares.

C Ordinary shares of £0.001 each

No voting rights attached to these shares; one equal right per share in any share dividend declared; one equal right per share in the distribution of any surplus due to the shareholders on a winding-up or other return of capital; no redemption right attach to these shares.

Incentive shares of £0.01 each

No voting rights for a period of 24 months following allotment, thereafter one vote per share, except where a founder ceases to be employed or engaged by, or appointed as a director of, or ceases to provide consultancy services to, the company, in which case any shares held by the same shall not carry voting rights unless otherwise determined by the Board.

Notes to the financial statements

3 Reserves

Share premium reserve

The share premium reserve is used to record the premium of the issue price for new issues of shares over the par value of those shares. The share premium reserve also records the costs directly attributable to the issue of new shares.

Capital redemption reserve

Capital redemption reserve records the nominal value of shares repurchased by the company.

Profit and loss

Includes all current and prior period retained profits and losses.